News
Eli Lilly sues four telehealth compounding GLP-1 companies
Eli Lilly is suing four telehealth companies that prescribe compounded versions of the pharmaceutical company's weight loss medications. Lilly filed four lawsuits on Wednesday claiming telehealth companies were misleading consumers and illegally prescribing compounded versions of its glucagon-like peptide-1 agonist drugs Mounjaro and Zepbound.
Hims & Hers (HIMS) stock in focus as a U.S. court denies injunction to continue making cheap versions of Novo Nordisk's (NVO) ...
A US judge on Thursday rejected a bid by compounding pharmacies to keep making copies of Novo Nordisk's popular diabetes and ...
HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it ...
The company's breakthrough puts the market one step closer to having an injection-free alternative for the treatment of ...
Eli Lilly and Co. shares surged after data showed its experimental weight-loss pill worked as well as the Ozempic shot.
Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...
Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...
Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling ...
Overall, Novo is expecting slower growth in 2025. The company is guiding for sales to rise between 16% and 24%, down from 26% ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback